2
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Completed
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Conditions
Carcinoma, Non-Small-Cell Lung
12
Neoplasms
5
Squamous Cell Carcinoma of Head and Neck
3
Small Cell Lung Carcinoma
3
Melanoma
3
Head and Neck Neoplasms
3
Colorectal Neoplasms
3
Urinary Bladder Neoplasms
2
Triple Negative Breast Neoplasms
2
Lymphoma, Non-Hodgkin
2
Lymphoma, B-Cell
2
Lung Neoplasms
2
Esophageal Neoplasms
2
Carcinoma, Squamous Cell
2
Carcinoma, Renal Cell
2
Carcinoma, Hepatocellular
2
Uterine Cervical Neoplasms
1
Urothelial Cancer
1
Stomach Neoplasms
1
Spinocerebellar Degenerations
1
Solid Tumors
1
Solid Tumor, Adult
1
Sarcoma
1
Rhabdoid Tumor
1
Rectal Neoplasms
1
Pancreatic Adenocarcinoma
1
PD-L1-selected Solid Tumors
1
Neoplasm Metastasis
1
Multiple Myeloma
1
Lymphoma, Follicular
1
Interventions
tucatinib
1
pralsetinib
1
pertuzumab
1
ipatasertib
1
inavolisib
1
entrectinib
1
atezolizumab
1
alectinib
1
Trastuzumab
1
Tiragolumab
1
Paclitaxel
1
Ado-Trastuzumab Emtansine
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Advanced Unresectable or Metastatic Solid Malignancy
×
Tiragolumab
×
Clear all
NCT04632992
2025-01-08
MyTACTIC
Genentech, Inc.
Phase 2
Completed
252 enrolled
27 charts